Remdesivir shortened recovery time for seriously ill patients by four days in a clinical trial comparing the drug with a placebo. Those results were considered so promising that a safety oversight committee stopped the clinical trial early to give people taking the placebo a chance to get the drug. Remdesivir will become the standard of care for the coronavirus. ScienceNews
Wednesday, May 13, 2020
The new COVID-19 drug remdesivir is here. Now what?
Remdesivir shortened recovery time for seriously ill patients by four days in a clinical trial comparing the drug with a placebo. Those results were considered so promising that a safety oversight committee stopped the clinical trial early to give people taking the placebo a chance to get the drug. Remdesivir will become the standard of care for the coronavirus. ScienceNews
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment